Skye Bioscience Inc. (SKYE)
NASDAQ: SKYE
· Real-Time Price · USD
2.45
0.30 (13.95%)
At close: Jun 06, 2025, 3:59 PM
2.42
-1.22%
After-hours: Jun 06, 2025, 05:55 PM EDT
Company Description
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases.
The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension.
It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Skye Bioscience Inc.
| Country | United States |
| IPO Date | Nov 26, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Punit S. Dhillon B.A. |
Contact Details
Address: 11250 El Camino Real San Diego, California United States | |
| Website | https://skyebioscience.com |
Stock Details
| Ticker Symbol | SKYE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001516551 |
| CUSIP Number | 83086J101 |
| ISIN Number | US83086J2006 |
| Employer ID | 45-0692882 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Punit S. Dhillon B.A. | President, Chief Executive Officer, Secretary & Director |
| Kaitlyn Melanie Arsenault CPA | Chief Financial Officer |
| Tu Diep M.Sc. | Chief Operating Officer |
| Brennen Brodersen J.D. | General Counsel |
| Dr. Christopher G. Twitty Ph.D. | Chief Scientific Officer |
| Dr. Puneet S. Arora FACE, M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 08, 2025 | 8-K | Current Report |
| May 08, 2025 | 10-Q | Quarterly Report |
| Apr 25, 2025 | 3 | Filing |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Mar 20, 2025 | S-8 | Filing |
| Mar 20, 2025 | 8-K | Current Report |